2 Followers on Owler

Casdin Capital

Casdin Capital is an investment firm focuses on disruptive businesses. Read more

CEO Avatar

CEO

Update CEO

CEO Approval Rating

- -/100

Founded:

06/2011

Status:

Investment CompanyIndependent Company

Est. Annual Revenue
Est. Employees
Sector

Update Industry

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Apple a competitor of Casdin Capital?

Casdin Capital Acquisitions

No recent acquisitions found related to Casdin Capital

Casdin Capital Funding History

No recent funding data found related to Casdin Capital

Casdin Capital Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

Mnemo is a France-based biotechnology company that develops and commercializes cell therapies for solid tumors and blood cancers.
$90M
Jun 15, 2021
Series A
-
Umoja is a Washington-based biotechnology company that develops and commercializes CAR T-cell therapies for the treatment of cancer.
$210M
Jun 14, 2021
Series B
-
LetsGetChecked is a New York-based health-tech company that develops sexual health, wellness assessment kits and related products for men and women.
$150M
Jun 06, 2021
Series D
-
NiKang is a Delaware-based biotechnology company that develops and commercializes small molecule medicines for the treatment of cancer.
$200M
May 25, 2021
Series C
-
Vedere Bio is a biopharmaceutical company that researches and develops ocular gene therapies for the treatment of eye disorders.
$77M
May 17, 2021
Series A
Oct 01, 2020

Casdin Capital News

June 8, 2021VatorNews

LetsGetChecked raises $150M to expand its virtual care platform

The at-home testing company will also provide patients with telemedicine and pharmacy servicesAt-home... See more »
June 8, 2021MedCity News

LetsGetChecked passes $1B valuation, plans broader telehealth play

The at-home testing startup plans to launch a broader virtual care offering after raising $150 millio... See more »
June 7, 2021SiliconRepublic

LetsGetChecked valued at $1bn after $150m funding round

The health tech start-up has pushed into coronavirus testing and will now expand into additional virt... See more »
May 31, 2021FinSMEs

NiKang Therapeutics Raises $200M in Series C Financing

NiKang Therapeutics Inc., a Wilmington,...... See more »
May 27, 2021Pharamceutical Technology

NiKang Therapeutics secures $200m in Series C funding

NiKang Therapeutics has secured $200m in a Series C funding round to develop new small molecules for ... See more »
May 21, 2021Global University Venturing

News, Data, and Events - Global University Venturing

The UC Berkeley spinout-derived genetic eye disease therapeutics company has launched with fresh fund... See more »
May 18, 2021BioSpace

Vedere Bio II Launches with $77 Million Series A Financing to Develop Next Generation Ocular Gene Therapies

Uses novel, mutation agnostic optogenetics approach to restore vision in underserved forms of blindne... See more »

Casdin Capital Press Releases

September 30, 2020Business Wire

Invetx Announces Completion of $25.5 Million Series A Financing and Key Appointments to Executive Team

BOSTON--(BUSINESS WIRE)--Invetx Announces Completion of $25.5 Million Series A Financing and Key Appo... See more »
September 14, 2020EIN Presswire

NiKang Therapeutics Completes $50 Million Series B Financing

Funds will support advancing lead programs into the clinic and expanding the company's pipeline. This... See more »
July 1, 2020PR Newswire

Genome Medical Raises $14 Million to Expand Virtual Clinical Genetics Care and Accelerate Telemedicine Technology Development

SOUTH SAN FRANCISCO, Calif., July 1, 2020 /PRNewswire/ -- Genome Medical, a leading telegenomics tech... See more »
June 10, 2020centralcharts

Fulcrum Therapeutics Completes $68.5 Million Private Placement

CAMBRIDGE, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC) today a... See more »
April 9, 2020Business Wire

Tango Therapeutics Raises $60 Million Series B Financing and Strengthens Executive Team

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tango Therapeutics raises $60 million Series B financing round and... See more »
January 11, 2016Business Wire

Syros Pharmaceuticals Closes $40 Million Preferred Stock Financing

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals today announced the closing of a $40 million... See more »

Social Media

Casdin Capital Headquarters

1350 Avenue of the Americas Suite 1140

New York, New York10019

212-897-5430

Driving Directions »

Trending Companies

Casdin Capital Summary

ABOUT

Overview

Casdin Capital is an investment firm focuses on disruptive businesses. Casdin Capital was founded in 06/2011. Casdin Capital's headquarters is located in New York, New York, USA 10019. ...

Frequently Asked Questions about Casdin Capital

  1. When was Casdin Capital founded?

    Casdin Capital was founded in 06/2011
  2. How much revenue does Casdin Capital generate?

    Casdin Capital generates $12.9M in revenue
  3. How much funding does Casdin Capital have?

    Casdin Capital has historically raised $0 in funding
  1. Where is Casdin Capital's headquarters?

    Casdin Capital's headquarters is in New York New York, USA
  2. How many employees does Casdin Capital have?

    Casdin Capital has 10 employees
  3. Who has Casdin Capital invested in?

    Casdin Capital's has invested in companies such as Mnemo, Umoja, LetsGetChecked